Serina Therapeutics (NYSEAMERICAN:SER) Director Karen Wilson Acquires 10,000 Shares

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Director Karen Wilson bought 10,000 shares of the company’s stock in a transaction on Thursday, May 21st. The stock was bought at an average cost of $1.77 per share, for a total transaction of $17,700.00. Following the completion of the transaction, the director directly owned 10,000 shares of the company’s stock, valued at $17,700. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Serina Therapeutics Stock Performance

Shares of NYSEAMERICAN:SER traded down $0.06 on Tuesday, hitting $1.92. The company’s stock had a trading volume of 97,959 shares, compared to its average volume of 2,884,637. The firm has a market capitalization of $28.80 million, a P/E ratio of -0.96 and a beta of 1.15. The company’s 50-day moving average price is $1.95. Serina Therapeutics, Inc. has a 12 month low of $1.22 and a 12 month high of $7.92. The company has a quick ratio of 4.18, a current ratio of 4.18 and a debt-to-equity ratio of 0.24.

Serina Therapeutics (NYSEAMERICAN:SER) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.58) earnings per share (EPS) for the quarter.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.